Clinical Chemistry, Immunology and Laboratory Quality Control: A Comprehensive Review for Board Preparation, Certification and Clinical Practice

Clinical Chemistry, Immunology and Laboratory Quality Control: A Comprehensive Review for Board Preparation, Certification and Clinical Practice

Volumn , Issue , 2014, Pages 1-483

  Dasgupta, Amitava ^a   Wahed, Amer ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84902714169     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/C2012-0-06507-6     Document Type: Book

References (325)

1. Dasgupta A., Zaidi S., Johnson M., Chow L., Wells A. Use of fluorescence polarization immunoassay for salicylate to avoid positive/negative interference by bilirubin in the Trinder salicylate assay. Ann Clin Biochem 2003, 40:684-688.
2. Profrock D., Prange A. Inductively couples plasma-mass spectrometry (ICP-MS) for quantitative analysis in environmental and life sciences: a review of challenges, solutions and trends. Appl Spectrosc 2012, 66:843-868.
3. James A.T., Martin A.J.P. Gas-liquid partition chromatography: the separation and micro-estimation of volatile fatty acids from formic acid to dodecanoic acid. Biochem J 1952, 50:679-690.
4. Proeless H.F., Lohmann H.J., Miles D.G. High performance liquid-chromatographic determination of commonly used tricyclic antidepressants. Clin Chem 1978, 24:1948-1953.
5. Subramanian M., Birnbaum A.K., Remmel R.P. High-speed simultaneous determination of nine antiepileptic drugs using liquid chromatography-mass spectrometry. Ther Drug Monit 2008, 30:347-356.
6. Verbesselt R., Tjandramaga T.B., de Schepper P.J. High-performance liquid chromatographic determination of 12 antiarrhythmic drugs in plasma using solid phase extraction. Ther Drug Monit 1991, 13:157-165.
7. Dasgupta A., Rosenzweig I.B., Turgeon J., Raisys V.A. Encainide and metabolites analysis in serum or plasma using a reversed-phase high-performance liquid chromatographic technique. J Chromatogr 1990, 526:260-265.
8. Jolley M.E., Stroupe S.D., Schwenzer K.S., Wang CJ, et al. Fluorescence polarization immunoassay III. An automated system for therapeutic drug determination. Clin Chem 1981, 27:1575-1579.
9. Jeon S.I., Yang X., Andrade J.D. Modeling of homogeneous cloned enzyme donor immunoassay. Anal Biochem 2004, 333:136-147.
10. Snyder J.T., Benson C.M., Briggs C., et al. Development of NT-proBNP, Troponin, TSH, and FT4 LOCI(R) assays on the new Dimension (R) EXL with LM clinical chemistry system. Clin Chem 2008, 54:A92. [Abstract #B135].
11. Dai J.L., Sokoll L.J., Chan D.W. Automated chemiluminescent immunoassay analyzers. J Clin Ligand Assay 1998, 21:377-385.
12. Forest J.-C., Masse J., Lane A. Evaluation of the analytical performance of the Boehringer Mannheim Elecsys® 2010 Immunoanalyzer. Clin Biochem 1998, 31:81-88.
13. Babson A.L., Olsen D.R., Palmieri T., Ross AF, et al. The IMMULITE assay tube: a new approach to heterogeneous ligand assay. Clin Chem 1991, 37:1521-1522.
14. Christenson R.H., Apple F.S., Morgan D.L. Cardiac troponin I measurement with the ACCESS® immunoassay system: analytical and clinical performance characteristics. Clin Chem 1998, 44:52-60.
15. Montagne P., Varcin P., Cuilliere M.L., Duheille J. Microparticle-enhanced nephelometric immunoassay with microsphere-antigen conjugate. Bioconjugate Chem 1992, 3:187-193.
16. Henry N., Sebe P., Cussenot O. Inappropriate treatment of prostate cancer caused by heterophilic antibody interference. Nat Clin Pract Urol 2009, 6:164-167.
17. Georges A., Charrie A., Raynaud S., Lombard C., et al. Thyroxin overdose due to rheumatoid factor interferences in thyroid-stimulating hormone assays. Clin Chem Lab Med 2011, 49:873-875.
18. Tang G., Wu Y., Zhao W., Shen Q. Multiple immunoassays systems are negatively interfered by circulating cardiac troponin I autoantibodies. Clin Exp Med 2012, 12:47-53.
19. Verhoye E., Bruel A., Delanghe J.R., Debruyne E, et al. Spuriously high thyrotropin values due to anti-thyrotropin antibody in adult patients. Clin Chem Lab Med 2009, 47:604-606.
20. Kavanagh L., McKenna T.J., Fahie-Wilson M.N., et al. Specificity and clinical utility of methods for determination of macro-prolactin. Clin Chem 2006, 52:1366-1372.
21. Matama S., Ito H., Tanabe S., Shibuya A., et al. Immunoglobulin complexed aspartate aminotransferase. Intern Med 1993, 32:156-159.
22. Er T.K., Jong Y.J., Tsai E.M., Huang C.L., et al. False positive pregnancy in hydatidiform mole. Clin Chem 2006, 52:1616-1618.
23. Carraro P., Plebani M. Errors in STAT laboratory; types and frequency 10 years later. Clin Chem 2007, 53:1338-1342.
24. Murphy J.E., Ward E.S. Elevated phenytoin concentration caused by sampling through the drug-administered line. Pharmacotherapy 1991, 11. 348-350.
25. Dunn E.J., Morga P.J. Patient misidentification in laboratory medicine: a qualitative analysis of 227 root cause analysis reports in the Veteran Administration. Arch Pathol Lab Med 2010, 134:244-255.
26. Aleccia J. Patients still stuck with bill for medical errors. 2008 2/29/2008 8:26:51 AM ET [cited 2012 06/28/2012]; Available from: <>. http://www.msnbc.msn.com/id/23341360/ns/health-health_care/t/patients-still-stuck-bill-medical-errors/#.T-yk5vVibJs.
27. Lee D.C., Klachko M.N. Falsely elevated lithium levels in plasma samples obtained in lithium containing tubes. J Toxicol Clin Toxicol 1996, 34:467-469.
28. Knowles T.P., Mullin R.A., Hunter J.A., Douce F.H. Effects of syringe material, sample storage time, and temperature on blood gases and oxygen saturation in arterialized human blood samples. Respir Care 2006, 51:732-736.
29. Toffaletti J., Blosser N., Kirvan K. Effects of storage temperature and time before centrifugation on ionized calcium in blood collected in plain vacutainer tubes and silicone-separator (SST) tubes. Clin Chem 1984, 30(4):553-556.
30. Jenny R.W., Jackson K.Y. Proficiency test performance as a predictor of accuracy of routine patient testing for theophylline. Clin Chem 1993, 39:76-81.
31. Theolen D., Lawson N.S., Cohen T., Gilmore B. Proficiency test performance and experience with College of American Pathologist's programs. Arch Pathol Lab Med 1995, 119:307-311.
32. Boone D.J. Literature review of research related to the Clinical Laboratory Improvement Amendments of 1988. Arch Pathol Lab Med 1992, 116:681-693.
33. Armbuster D.A., Pry T. Limit of blank, limit of detection and limit of quantification. Clin Biochem Rev 2008, 29(Suppl. 1):S49-S51.
34. Dasgupta A., Tso G., Chow L. Comparison of mycophenolic acid concentrations determined by a new PETINIA assay on the Dimension EXL analyzer and a HPLC-UV method. Clin Biochem 2013, 46:685-687.
35. Turban S., Thompson C.B., Parekh R.S., Appel L.J. Effects of sodium intake and diet on racial difference in urinary potassium excretion: results from the Dietary Approaches to Stop Hypertension (DASH) sodium trial. Am J Kidney Dis 2013, 61:88-95.
36. Kobayashi T., Miwa T., Odawara M. A case of central diabetes insipidus following probable type A/H1N1 influenza infection. Endocr J 2011, 58:913-918.
37. Cohen C., Rice E.N., Thomas D.E., Carpenter T.O. Diabetes insipidus as a hallmark neuroendocrine complication of neonatal meningitis. Curr Opin Pediatr 1998, 10:449-452.
38. Sceinpflug K., Schalk E., Reschke K., Franke A., et al. Diabetes insipidus due to herpes encephalitis in a patient with diffuse large cell lymphoma: a case report. Exp Clin Endocrinol Diabetes 2006, 114:31-34.
39. Devuyst O. Physiology and diagnosis of nephrogenic diabetes insipidus. Ann Endocrinol (Paris) 2012, 73:128-129.
40. Pillai B., Unnikrishnan A.G., Pavithran P. Syndrome of inappropriate antidiuretic hormone secretion: revisiting a classical endocrine disorder. Indian J Endocrinol 2011, 15(Suppl. 3):S208-S215.
41. Gill G.V., Osypiw J.C., Shearer E.S., English P.J., et al. Critical illness with hyponatremia and impaired cell membrane integrity-the sick cell syndrome revisited. Clin Biochem 2005, 38:1045-1048.
42. Richman T., Garmany R., Doherty T., Benson D., et al. Hypokalemia, metabolic alkalosis, and hypertension: Cushing's syndrome in a patient with metastatic prostate. Am J Kidney Dis 2001, 37:838-846.
43. Perazella M.A. Drug induced hyperkalemia: old culprits and new offenders. Am J Med 2000, 109:307-314.
44. Rifkin S. Pseudohyperkalemia in a patient with chronic lymphocytic leukemia. Int J Nephrol 2011, [Article ID 759749].
45. Sawle A., Higgins M.K., Olivant M.P., Higgins J.A. A rapid single step centrifugation method for determination of HDL, LDL and VLDL cholesterol and TG and identification of predominant LDL subclass. J Lipid Res 2002, 43:335-343.
46. Yusuf S., Hawken S., Ounpuu S., Dans T., et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case control study. Lancet 2004, 364:937-952.
47. Kones R. Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management: A comprehensive survey. Drug Des Devel Ther 2011, 5:325-380.
48. Gordon T., Kannel W.B., Castelli W.P., Dawber T.R. Lipoproteins, cardiovascular disease and death. The Framingham study. Arch Intern Med 1981, 141:1128-1131.
49. Vijayakrishnan R., Kalyatanda G., Srinivasan I., Abraham G.M. Compliance with the adult treatment panel III guidelines for hyperlipidemia in a resident run ambulatory clinic: a retrospective study. J Clin Lipidol 2013, 7:43-47.
50. Law M.R., Wald N.J. Risk factor thresholds: their existence under scrutiny. BMJ 2003, 327:518.
51. Grundy S.M., Cleeman J.I., Merz C.N., Brewer H.B., et al. Implications of recent clinical trials for National Cholesterol Education Program Adult Treatment Panel III guidelines. J Am Coll Cardiol 2004, 44:720-732.
52. Martin S.S., Blumenthal R.S., Miller M. LDL cholesterol: lower the better. Med Clin North Am 2012, 96:13-26.
53. Miller M., Stone N.J., Ballantyne C., Bittner V., et al. Triglycerides and cardiovascular disease: a scientific statement from American Heart Association. Circulation 2011, 123:2292-2333.
54. Cheung M.C., Mendez A.J., Wolf A.C., Knopp R.H. Characteristics of apolipoprotein A-1 and A-II containing lipoproteins in a new case of high density lipoprotein deficiency resembling Tangier disease and their effects on intracellular cholesterol efflux. J Clin Invest 1993, 91:522-529.
55. Liu J., Sempos C.T., Donahue R.P., Dorn J., et al. Non high density lipoprotein and very low density lipoprotein cholesterol and their risk predictive values in coronary heart disease. Am J Cardiol 2006, 98:1363-1368.
56. Ballantyne C.M., Raichlen J.S., Cain V.A. Statin therapy alters the relationship between apolipoprotein B and low density lipoprotein cholesterol and non-high density lipoprotein cholesterol targets in high risk patients: the MERCURY II (measuring effective reductions in cholesterol using rosuvastatin) trial. J Am Coll Cardiol 2008, 52:626-632.
57. Goswami B., Rajappa M., Malika V., Kumar S., et al. Apo B/Apo AI ratio, a better discriminator for coronary artery disease risk than other conventional lipid ratios in Indian patients with acute myocardial infarction. Acta Cardiol 2008, 63:749-755.
58. Warner C., Rader D., Bartens W., Kramer J., et al. Elevated plasma lipoprotein (a) in patients with nephrotic syndrome. Ann Intern Med 1993, 119:263-269.
59. Tamaki W, Fujieda M, Madda M, Hasokawa T, et al. A case of pseudohomozygous type II hyperlipoproteinemia in early infancy. Pediatr Int 2011;110-113.
60. Roheim P.S., Asztalos B.F. Clinical significance of lipoprotein size and risk for coronary atherosclerosis. Clin Chem 1995, 41:147-152.
61. McGully K.S. Homocystinuria, arteriosclerosis, methylmalonic aciduria and methyltransferase deficiency: a key case revisited. Nutr Rev 1992, 50:7-12.
62. Jacques P.F., Bostom A.G., Williams R.R., Ellison RC, et al. Relation between folate status a common mutation in methylene tetrahydrofolate reductase and plasma homocysteine concentration. Circulation 1996, 93:7-9.
63. Lee J.H., Park J.E., Lee S.H., Kim J.R., et al. Elevated HDL2-paraoxonase and reduced CETP activity are associated with a dramatically lower ratio of LDL cholesterol/total cholesterol in a hypercholesterolemic and hypertriglyceridemic patient. Int J Mol Med 2010, 25:945-951.
64. Julius U., Fischer S. Nicotinic acid as a lipid modifying drug-a review. Atheroscler Suppl 2013, 14:7-13.
65. Fajans S.S., Graeme I.B., Polonksy K.S. Molecular mechanisms and clinical pathophysiology of maturity-onset diabetes in the young. N Eng J Med 2001, 345:971-980.
66. Johansson S., Irgens H., Chudssama K.K., Molnes J., et al. Exon sequencing and genetic testing for MODY. PLoS One 2012, 7:e38050.
67. Murphy R., Ellard S., Hattersley A.T. Clinical implications of a molecular genetics classification of monogenic beta-cell diabetes. Nat Clin Pract Endocrinol Metab 2008, 4:200-213.
68. Henzen C. Monogenic diabetes mellitus due to defect in insulin secretion. Swiss Med Wkly 2012, 142:w13690.
69. Balkau B., Valensi P., Eschwege E., Slama G. A review of metabolic syndrome. Diabetes Metab 2007, 33:405-413.
70. Cebeci A., Guven A. Delirium in diabetic ketoacidosis: a case report. J Clin Res Pediatr Endocrinol 2012, 4:39-41.
71. Palmer C., Jessup A. Ketoacidosis in patients with type 2 diabetes. Nurs Pract 2012, 37:13-17.
72. International expert committee report on the role of the A1C assay in the diagnosis of diabetes mellitus. Diabetes Care 2009, 32:1327-1334. International Expert Committee.
73. Hellman R. Glucose meter inaccuracy and the impact on the care of patients. Diabetes Metab Res Rev 2012, 28:207-209.
74. Kelly B.N., Haverstick D.M., Bruns D. Interference in a glucose dehydrogenase based glucose meter. Clin Chem 2010, 56:1038-1040.
75. Trask L., Abbott D., Lee H.K. Low hemoglobin A1c: good diabetic control?. Clin Chem 2012, 58:648-649.
76. Shanthi B., Revathy C., Manjula Devi A.J., Subhashree Effect of iron deficiency on glycation of haemoglobin. J Clin Diagn Res 2013, 7:15-17.
77. Chen H.S., Wu T.E., Lin H.D., Jap T.S., et al. Hemoglobin A (1c) and fructosamine for assessing glycemic control in diabetic patients with CKD stage 3 and 4. Am J Kidney Dis 2010, 55:867-874.
78. Movahed MR, John J, Hashemzadeh M, Hashemzadeh M. Mortality trends in non-ST-segment elevation myocardial infarction (NSTEMI) in the United States from 1998 to 2004. Clin Cardiol 2011, 34:689-692.
79. Wright RS, Anderson JL, Adams CD, Bridges CR, et al. ACCF/AHA focused update of the guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating 2007 guidelines). J Am Coll Cardiol 2011, 57:1920-1959.
80. Adams CD, Antman EM, Bridges CR, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of American College of Cardiology/American Heart Association task force on practice guidelines. Circulation 2007, 116:e148-e304.
81. Lackner KJ. Laboratory diagnostics of myocardial infarction-troponins and beyond. Clin Chem Lab Med 2013, 51:83-89.
82. Kasaoka S, Todani M, Kaneko T, Kawamura Y, et al. Peak value of blood myoglobin predicts acute renal failure induced by rhabdomyolysis. J Critical Care 2010, 25:601-604.
83. Woo J, Lacbawan FL, Sunheimer R, LeFever D, et al. Is myoglobin useful in the diagnosis of acute myocardial infarction in the emergency department setting?. Am J Clin Pathol 1995, 103:725-729.
84. Lawandrowski K, Chen A, Januzzi J. Cardiac markers for myocardial infarction. Am J Clin Pathol 2002, 118(Suppl.):S93-S99.
85. Lee T, Goldman L. Serum enzymes in the diagnosis of acute myocardial infarction. Ann Intern Med 1986, 105:221-233.
86. Lee KN, Casko G, Bernhardt P, Elin R. Relevance of macro creatinine kinase type 1 and type 2 isoenzymes to laboratory and clinical data. Clin Chem 1994, 40:1278-1283.
87. Er TK, Ruiz Gines MA, Jong YJ, Tsai LY, et al. Identification of false positive creatinine kinase-MB activity in a patient with nonketonic hyperglycemia. Am J Med 2007, 859:e9-e10.
88. Ferguson JL, Beckett GJ, Stoddart M, Fox KAA Myocardial infarction redefined: the new ACC/ESC definition, based on cardiac troponin, increases the apparent incidence of infarction. Heart 2002, 88:343-347.
89. Hamm CW, Giannitsis E, Katus HA. Cardiac troponin elevations in patients without acute coronary syndrome. Circulation 2002, 106:2871-2872.
90. Panteghini M, Bunk DM, Christenson RH, Katrukha A, et al. Standardization of troponin I measurements: an update. Clin Chem Lab Med 2008, 46:1501-1506.
91. Michielsen EC, Bisschops PG, Janssen MJ. False positive troponin result caused by a true macrotroponin. Clin Chem Lab Med 2011, 49:923-925.
92. Salah AK, Gharad SM, Bodiwala K, Booth DC. You can assay it again. Am J Med 2007, 120:671-672.
93. Twernbold R, Reichlin T, Reiter M, Muller C. High-sensitive cardiac troponin: friend or foe?. Swiss Med Wkly 2011, 141:w13202.
94. Dekker MS, Mosterd A, van Hof A, Hoes AW. Novel biomarkers in suspected acute coronary syndrome: systematic review and critical appraisal. Heart 2010, 96:1001-1010.
95. Weber M, Hamm C. Role of B-type natriuretic peptide (BNP) and NT-proBNP in clinical routine. Heart 2006, 92:843-849.
96. Kostoglou-Athanassiou I. Therapeutic application of melatonin. Ther Adv Endocrinol Metab 2013, 4:13-24.
97. Lee H.J., Macbeth A.H., Pagani J., Young W.S. Oxytocin: the great facilitator of life. Prog Neurobiol 2009, 88:127-151.
98. Pauche J.E., Castilla-Cortazar I. Human conditions of insulin-like growth factor-1 (IGF-1) deficiency. J Transl Med 2012, 10:224.
99. Todd C.H. Management of thyroid disorders in primary care challenges and controversies. Postgrad Med J 2009, 85:655-659.
100. Loh T.P., Kao S.L., Halsall D.J., Toh S.A., et al. Macro-thyrotropin: a case report and review of literature. J Clin Endocrinol Metab 2012, 97:1823-1828.
101. Dufour D.R. Laboratory tests of thyroid function: use and limitations. Endocrinol Metab Clin N Am 2007, 36:579-594.
102. Zaletel K., Gaberscek S. Hashimoto's thyroidititis: from genes to the disease. Curr Genomics 2011, 12:576-588.
103. Gaitonde D., Rowley K., Sweeney L.B. Hypothyroidism: an update. Am Fam Physician 2012, 86:244-251.
104. Jurecka-Lubieniecka B., Ploski R., Kula D., Krol A., et al. Association between age at diagnosis of Graves' disease and variants in genes involved in immune response. PLoS One 2013, 8(3):e59349.
105. Reid J.R., Wheeler S.F. Hyperthyroidism: diagnosis and treatment. Am Fam Physician 2005, 72:623-630.
106. Hamasaki H., Yoshimi T., Yanai H. A patient with Graves' disease showing only psychiatric symptoms and negativity for both TSH receptor autoantibody and thyroid stimulating antibody. Thyroid Res 2012, 5:19.
107. Ravikumar D., Lin M. A 37 year old woman with altered mental status and urinary frequency. West J Emerg Med 2013, 14:177-179.
108. Mouallem M., Shaharabany M., Weintrob N., Shalitin S., et al. Cognitive impairment is prevalent in pseudohypoparathyroidism type Ia, but not in pseudopseudohypoparathyroidism: possible cerebral imprinting of Gsalpha. Clin Endocrinol (Oxf) 2008, 68:233-239.
109. Vilar L., Freitas Mda C., Faria M., Montenegro R., et al. Pitfalls in the diagnosis of Cushing's syndrome. Arq Bras Endocrinol Metabol 2007, 51:1207-1216.
110. Besemer F., Pireira A.M., Smit J.W. Alcohol induced Cushing syndrome: hypercortisolism cause by alcohol abuse. Neth J Med 2011, 69:318-323.
111. Mise K., Ubara Y., Sumida K., Hiramatsu R., et al. Cushing's syndrome after hemodialysis for 21 years. J Clin Endocrinol Metab 2013, 98:13-19.
112. Mitchell A.L., Pearce S.H. Autoimmune Addison's disease: pathophysiology and genetic complexity. Nat Rev Endocrinol 2012, 8:306-316.
113. Ferreira F., Martins J.M., do Vale S., Esteves R., et al. Rare and severe complications of congenital adrenal hyperplasia due to 21 hydroxylase deficiency: a case report. J Med Case Rep 2013, 6:39.
114. Teede H., Deeks A., Moran L. Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the life span. BMC Med 2010, 8:41.
115. Kim E.U., Oh M.C., Lee E.J., Kim S.H. Predicting long term remission by measuring immediate postoperative growth hormone levels and oral glucose tolerance test in acromegaly. Neurosurgery 2012, 70:1106-1113.
116. Lekkakou L., Tzanela M., Lymberi M., Consoulas C., et al. Effects of gender and age on hypothalamic-pituitary-adrenal reactivity after pharmacological challenge with low dose 1μg ACTH test: a prospective study in healthy adults. Clin Endocrinol (Oxf) 2013; Mar, 10. [e-pub ahead of print].
117. Tynjala J., Kangastupa P., Laatikainen T., Aalto M., et al. Effect of age and gender on the relationship between alcohol consumption and serum GGT: time to recalibrate goals for normal ranges. Alcohol Alcohol 2012, 47:558-562.
118. Lee W.C., Kuo L.C., Cheng Y.C., Chen C.W., et al. Combination of white blood cell count with liver enzymes in the diagnosis of blunt liver laceration. Am J Emerg Med 2010, 28:1024-1029.
119. Ritchie A.H., Willscroft D.M. Elevated liver enzymes as a predictor of liver injury in stable blunt abdominal trauma patients: case report and systematic review of the literature. Can J Rural Med 2006, 11:283-287.
120. Schwertner H.A., Vitek L. Gilbert syndrome UGT1A1*28 allele and cardiovascular disease risk: possible protective effects and therapeutic applications of bilirubin. Atherosclerosis 2008, 198:1-11.
121. Passuello V., Puhl A.G., Wirth S., Steiner E., et al. Pregnancy outcome in maternal Crigler-Najjar syndrome Type II: a case report and systematic review of literature. Fetal Diagn Ther 2009, 26:121-126.
122. Winger J., Mchelfelder A. Diagnostic approach to the patients with jaundice. Prim Care Clin Office Pract 2011, 38:469-482.
123. DeBarkey SF, Stinson FS, Grant BF, Dufour MC. Surveillance report #41. Liver cirrhosis mortality in the United States 1970-1993. National Institute of Alcohol Abuse and Alcoholism, 1996.
124. Prescott L.F. Paracetamol, alcohol and the liver. Br J Clin Pharmacol 2000, 49:291-301.
125. Greenes V., Willamson C. Intrahepatic cholestasis of pregnancy. World J Gastroenterol 2009, 15:2049-2066.
126. Ko H.H., Yoshida E. Acute fatty liver of pregnancy. Can J Gastroenterol 2006, 20:25-30.
127. Jangaard K.A., Curtis H., Goldbloom R.B. Estimation of bilirubin using BiliChek, a transcutaneous bilirubin measurement device: effect of gestational age and use of phototherapy. Paediatr Child Health 2006, 11:79-83.
128. Szmuness W., Stevens C.E., Harley E.J., Zang E.A., et al. Hepatitis B vaccine in medical staff of hemodialysis units: efficacy and subtype cross-protection. N Engl J Med 1982, 307(24):1481.
129. Khan K.A., Akram J., Fazal M. Hormonal cations of vitamin D and its role beyond just a vitamin: a review article. Int J Med Mol Med 2011, 3:65-72.
130. Snyder S., Pendergraph B. Detection and evaluation of chronic kidney disease. Am Fam Physician 2005, 72:1723-1732.
131. Stevens L., Coresh J., Greene T., Levey A.S. Assessing kidney function: measured and estimated glomerular filtration rate. N Eng J Med 2006, 345:2473-2483.
132. K/DQQI clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am J Kidney Dis 2002, 39(Suppl. 2):S1-S266. National Kidney Foundation.
133. Rosenthal S.H., Bokenkamp A., Hoffmann W. How to estimate GDR serum creatinine, serum cystatin C or equation?. Clin Biochem 2007, 40:153-161.
134. Hojs R., Bevc S., Ekhart R., Gorenjak M., et al. Serum cystatin C based equation compared to serum creatinine based equations for estimation of glomerular filtration rate in patients with chronic kidney disease. Clin Nephrol 2008, 70:10-17.
135. Yap L., Lamarche J., Peguero A., Courville C. Serum cystatin C verus serum creatinine in the estimation of glomerular filtration rate in rhabdomyolysis. J Ren Care 2011, 37:155-157.
136. Rachoin J.S., Dahar R., Moussallem C., Milcarek B., et al. The fallacy of the BUN: creatinine ratio in critically ill patients. Nephrol Dial Transplant 2012, 27:2248-2254.
137. Lillehoj E.P., Poulik M.D. Normal and abnormal aspects of proteinuria: Part I: Mechanisms, characteristics and analyses of urinary protein. Part II: Clinical considerations. Exp Pathol 1986, 29:1-28.
138. Samara M., Abcar A.C. False estimate of elevated creatinine. Perm J 2012, 16:51-52.
139. Liu W.S., Chung Y.T., Yang C.Y., Lin C.C., et al. Serum creatinine determined by Jaffe, enzymatic methods and isotope dilution liquid chromatography-mass spectrometry in patients under hemodialysis. J Clin Lab Anal 2012, 26:206-214.
140. Killorn E., Lim R.K., Rieder M. Apparent elevated creatinine after ingestion of nitromethane: interference with the Jaffe reaction. Ther Drug Monit 2011, 33:1-2.
141. Patel H. The abnormal urinalysis. Pediatr Clin N Am 2006, 53:325-327.
142. Brigden M.L., Edgell D., McPherson M., Leadbeater A., et al. High incidence of significant urinary ascorbic acid concentrations in west coast population-implications for routine urinalysis. Clin Chem 1992, 38:426-431.
143. Alfadhel M., Al-Thihli K., Moubayed H., Eyaid W., Zytkovicz TH. Drug treatment of inborn errors of metabolism: a systematic review. Arch Dis Child 2013, Mar:26. [e-pub ahead of print].
144. Lin H.J., Kwong A.M., Carter J.M., Ferreira B.F., et al. Extremely high phenylalanine levels in a newborn on parenteral nutrition: phenylketonuria in a neonatal intensive care unit. J Perinatol 2011, 31:507-510.
145. Allard P., Greiner A., Korson M.S., Zytkovicz T.H. Newborn screening for hepatorenal tyrosinemia by tandem mass spectrometry: analysis of succinylacetone extracted from dried blood spot. Clin Biochem 2004, 37:1010-1015.
146. Ferri L., Caciotti A., Cavicchi C., Rigoldi M., et al. Integration of PCR sequencing analysis with multiplex ligation dependent probe amplification for diagnosis of hereditary fructose intolerance. JIMD Reports 2012, doi:10.1007/8904_2012_125.
147. Iyer H., Sen M., Prasad C., Rupar C.A., et al. Coma, hyperammonemia, metabolic acidosis, and mutation: lessons learned in the acute management of late onset urea cycle disorders. Hemodial Int 2012, 16:95-100.
148. Kolker S., Christensen E., Leonard J., Greenberg C., et al. Diagnosis and management of glutaric aciduria type I-revised recommendations. J Inherit Metab Dis 2011, 34:677-694.
149. Schulze H., Sandhoff K. Lysosomal lipid storage disease. Cold Spring Harb Perspect Biol 2011, 3. [pii a004804].
150. Torres R.J., Puig J.G., Jinnah H.A. Update on the phenotypic spectrum of Lesch-Nyhan disease and its attenuated variants. Curr Rheumatol Rep 2012, 14:189-194.
151. Ozben T. Expanded newborn screening and confirmatory follow-up testing for inborn errors of metabolism detected by tandem mass spectrometry. Clin Chem Lab Med 2013, 51:157-176.
152. Lilja H., Christensson A., Dahlén U., Matikainen M.T., et al. T. Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. Clin Chem 1991, 37:1618-1625.
153. Hudson M.A., Bahnson R.R., Catalona W.J. Clinical use of prostate specific antigen in patients with prostate cancer. J Urol 1989, 142(4):1011-1017.
154. Tanguay S., Bégin L.R., Elhilali M.M., Behlouli H., et al. Comparative evaluation of total PSA, free/total PSA, and complexed PSA in prostate cancer detection. Urology 2002, 59:261-265.
155. Sokoll L.J., Sanda M.G., Feng Z., Kagan J., et al. A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness. Cancer Epidemiol Biomarkers Prev 2010, 19:1193-1200.
156. Kilpelainen T.P., Tammela T.L., Roobol M., Hugosson J., et al. False positive screening results in the European randomized study of screening for prostate cancer. Eur J Cancer 2011, 47:2698-2705.
157. Morgan B.R., Tarter T.H. Serum heterophilic antibodies interfere with prostate specific antigen test and result in over treatment in a patient with prostate cancer. J Urol 2001, 166:2311-2312.
158. Henry N., Sebe P., Cussenot O. Inappropriate treatment of prostate cancer caused by heterophilic antibody interference. Nat Clin Pract Urol 2009, 6:164-167.
159. Hu K.Q., Kyulo N.L., Lim N., Elhazin B., et al. Clinical significance of elevated alpha-fetoprotein (AFP) in patients with chronic hepatitis C, but not hepatocellular carcinoma. Am J Gastroenterol 2004, 99(5):860-864.
160. Howaizi M., Abboura M., Krespine C., Sbai-Idrissi M.S., et al. A new case of CA-19-9 elevation: heavy tea consumption. Gut 2003, 52:913-914.
161. Pang Y.P., Rajesh H., Tan L.K. Molar pregnancy with false negative urine hCG; The hook effect. Singapore Med J 2010, 51:e58-e61.
162. Koshida S., Asanuma K., Kuribayashi K., Goto M., et al. Prevalence of human anti-mouse antibodies (HAMAs) in routine examination. Clin Chim Acta 2010, 411:391-394.
163. Gallagher D.J., Riches J., Bajorin D.F. False positive elevation of human chorionic gonadotropin in a patient with testicular cancer. Nat Rev Urol 2010, 7:230-233.
164. Mattson R.H., Cramer J.A., Collins J.F. Aspects of compliance: taking drugs and keeping clinic appointments. Epilepsy Res Suppl 1988, 1:111-117.
165. Chandra R.S., Dalvi S.S., Karnad P.D., Kshirsagar N.A., et al. Compliance monitoring in epileptic patients. J Assoc Physicians India 1993, 41:431-432.
166. Babalik A., Babalik A., Mannix S., Francis D., et al. Therapeutic drug monitoring in the treatment of active tuberculosis. Can Respir J 2011, 18:225-229.
167. Jeong H. Altered drug metabolism during pregnancy: hormonal regulation of drug metabolizing enzymes. Expert Opin Drug Metab Toxicol 2010, 6:689-699.
168. Anderson G.D. Pregnancy induced changes in pharmacokinetics: a mechanistic based approach. Clin Pharmacokinet 2005, 44:989-1008.
169. Terrell K.M., Heard K., Miller D.K. Prescribing to older ED patients. Am J Emerg Med 2006, 24:468-478.
170. Benowitz N.L., Meister W. Pharmacokinetics in patients with cardiac failure. Clin Pharmacokinet 1976, 1:389-405.
171. Betteridge T., Fink J. Phenytoin toxicity and thyroid dysfunction. NZ Med J 2009, 122:102-104.
172. Bailey D.G., Spence J.D., Munoz C., Arnold J.M. Interaction of citrus juices with felodipine and nifedipine. Lancet 1991, 337:268-269.
173. Saito M., Hirata-Koizumi M., Matsumoto M., Urano T., Hasegawa R. Undesirable effects of citrus juice on the pharmacokinetics of drugs: focus on recent studies. Drug Saf 2005, 28:677-694.
174. Koski A., Vuori E., Ojanpera I. Relation of postmortem blood alcohol and drug concentrations in fetal poisonings involving amitriptyline, propoxyphene and promazine. Hum Exp Toxicol 2005, 24:389-396.
175. Zevin S., Benowitz N.L. Drug interactions with tobacco smoking: an update. Clin Pharmacokinetic 1999, 36:425-438.
176. Kroon L.A. Drug interactions and smoking: raising awareness for acute and critical care provider. Crit Care Nurs Clin N Am 2006, 18:53-62.
177. Colucci V.J., Knapp J.E. Increase in International normalization ratio associated with smoking cessation. Ann Pharmacother 2001, 35:385-386.
178. Discoll D.E., McMahon M., Blackburn G.L., Bistrian B.R. Phenytoin toxicity in a critically ill hypoalbuminemic patient with normal serum drug concentration. Crit Care Med 1998, 16:1248-1249.
179. Rosansky S.J., Bradt M.E. Procainamide toxicity in a patient with acute renal failure. Am J Kidney Dis 1986, 7:502-506.
180. Tanaka T., Moretti M.E., Verjee Z.H., Shupak M., et al. A pitfall of measuring lithium levels in neonates. Ther Drug Monit 2008, 30:752-754.
181. Polson J., Wians F.H., Orsulak P., Fuller D., et al. False positive acetaminophen concentrations in patients with liver injury. Clin Chim Acta 2008, 391:24-30.
182. Dasgupta A., Zaldi S., Johnson M., Chow L., et al. Use of fluorescence polarization immunoassay for salicylate to avoid positive/negative interference by bilirubin in the Trinder salicylate assay. Ann Clin Biochem 2003, 40:684-688.
183. Dasgupta A. Therapeutic drug monitoring of digoxin: impact of endogenous and exogenous digoxin-like immunoreactive substances. Toxicol Rev 2006, 25:273-281.
184. Gruber K.A., Whitaker J.M., Buckalew V.M. Endogenous digitalis-like substances in plasma of volume expanded dogs. Nature 1980, 287:743-745.
185. Dasgupta A., Trejo O. Suppression of total digoxin concentration by digoxin-like immunoreactive substances in the MEIA digoxin assay: elimination of interference by monitoring free digoxin concentrations. Am J Clin Pathol 1999, 111:406-410.
186. Liendo C., Ghali J.K., Graves S.W. A new interference in some digoxin assays: anti-murine heterophilic antibodies. Clin Pharmacol Ther 1996, 60:593-598.
187. Tzou M.C., Reuning R.H., Sams R.A. Quantitation of interference in digoxin immunoassay in renal, hepatic and diabetic disease. Clin Pharm Ther 1997, 61:429-441.
188. Fyer F., Steimer W., Muller C., Zilker T. Free and total digoxin in serum during treatment of acute digoxin poisoning with Fab fragments; Case study. Am J Crit Care 2010, 19:387-391.
189. Steimer W., Muller C., Eber B. Digoxin assays: frequent, substantial and potentially dangerous interference by spironolactone, canrenone and other steroids. Clin Chem 2002, 48:507-516.
190. Parant F., Moulsma M., Gagnieu M.V., Lardet G. Hydroxyzine and metabolite as a source of interference in carbamazepine particle-enhanced turbidimetric inhibition immunoassay (PETINIA). Ther Drug Monit 2005, 27:457-462.
191. Annesley T., Kurzyniec S., Nordblom G., Buchanan N., et al. Glucuronidation of prodrug reactive site: isolation and characterization of oxymethylglucuronide metabolite of fosphenytoin. Clin Chem 2001, 46:910-918.
192. D'Alessandro M., Mariani P., Mennini G., Severi D., et al. Falsely elevated tacrolimus concentrations measures using the ACMIA method due to circulating endogenous antibodies in a kidney transplant recipient. Clin Chim Acta 2011, 412:245-248.
193. Simons S.A., Molinelli A.R., Sobhani K., Rainey P.M., Hoofnagle A. Two cases with unusual vancomycin measurements. Clin Chem 2009, 55:578-582.
194. Results from the 2010 National Survey on Drug Use and Health: National Findings: U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration (SAMHSA) Office of Applied Studies.
195. White A.M., Hingson R.W., Pan I.J., Yi H.Y. Hospitalization for alcohol and drug overdoses in young adults ages 18-24 in the United States, 1999-2008: results from the nationwide inpatient sample. J Stud Alcohol Drugs 2011, 72:774-786.
196. Yee L.M., Wu D. False positive amphetamine toxicology screen results in three pregnant women using labetalol. Obstet Gynecol 2011, 117:503-506.
197. Kreek M.J., Bart G., Lilly C., LaForge K.S., et al. Pharmacogenetics and human molecular genetics of opiate and cocaine addictions and their treatments. Pharmacol Rev 2005, 57:1-26.
198. Solomon M.D., Wright J.A. False-positive for (+)-methamphetamine. Clin Chem 1977, 23:1504.
199. Wyman J.F., Cody J.T. Determination of l-methamphetamine: a case history. J Anal Toxicol 2005, 29:759-761.
200. Rollins D.E., Jennison T.A., Jones G. Investigation of interference by non-steroidal antiinflammatory drugs in urine tests for abused drugs. Clin Chem 1990, 36:602-606.
201. Boucher A., Vilette P., Crassard N., Bernard N., et al. Urinary toxicology screening: analytical interference between niflumic acid and cannabis. Arch Pediatr 2009, 16:1457-1460. [article in French].
202. West R., Pesce A., West C., Crews B., et al. Comparison of clonazepam compliance by measurement of urinary concentration by immunoassay and LC-MS/MS in patient management. Pain Physician 2010, 13:71-78.
203. Von Seggern R.L., Fitzgerald C.P., Adelman L.C., Adelman J.U. Laboratory monitoring of OxyContin (oxycodone): clinical pitfalls. Headache 2004, 44:44-47.
204. Baker J.E., Jenkins A.J. Screening for cocaine metabolite fails to detect an intoxication. Am J Forensic Med Pathol 2008, 29:141-142.
205. Bailey K.M., Clay D.J., Gebhardt M.A., Schmidt M.J., et al. Cocaine detection in postmortem samples following therapeutic administration. J Anal Toxicol 2009, 33:550-552.
206. Dasgupta A., Chughtai O., Hannah C., Davis B., Wells A. Comparison of spot tests with AdultaCheck 6 and Intect 7 urine test strips for detecting the presence of adulterants in urine specimens. Clin Chem Acta 2004, 34:19-25.
207. Gonomori K., Yoshioka N. The examination of mushroom poisonings at Akita University. Leg Med (Tokyo) 2003, 5(Suppl. 1):S83-S86.
208. Halpern J.H., Sherwood A.R., Hudson J.I., Yugerlum-Todd D., Pope H.G. Psychological and cognitive effects of long term peyote use among Native Americans. Biol Psychiatry 2005, 58:624-631.
209. Nichols D.E. Hallucinogens. Pharmacol Ther 2004, 101:131-181.
210. Forsman M., Nystrom I., Roman M., Berglund L., et al. Urinary detection times and excretion patterns of flunitrazepam and its metabolites after a single oral dose. J Anal Toxicol 2009, 33:491-501.
211. Ohshima T. A case of drug facilitated sexual assault by the use of flunitrazepam. J Clin Forensic Med 2006, 13:44-45.
212. Tao L.Y., Chen X.P., Qin Z.H. A fatal chronic ketamine poisoning. J Forensic Sci 2005, 50:173-175.
213. Ortmann L.A., Jaeger M.W., James L.P., Schexnayder S.M. Coma in a 20 month old child from ingestion of a toy containing 1,4-butanediol, a precursor of gamma-hydroxybutyrate. Pediate Emerg Care 2009, 25:758-760.
214. Kintz P., Villain M., Pelissier A.L., Cirimele V., et al. Unusually high concentrations in a fatal GHB case. J Anal Toxicol 2005, 29:582-585.
215. Fass J.A., Fass A.D., Garcia A. Synthetic cathinones (bath salts): legal status and patterns of abuse. Annals Pharmacother 2012, 46:436-441.
216. Lusthof K.J., Oosting R., Maes A., Verschraagen M., et al. A case of extreme agitation and death after the use of mephedrone in the Netherlands. Forensic Sci Int 2011, 206:e93-e95.
217. Wells D., Ott C.A. The new marijuana. Annals Pharmacother 2011, 45:414-417.
218. ElSohly MA, Gul W, Elsohly KM, Murphy TP, et al. Liquid chromatography-tandem mass spectrometry analysis of urine specimens for K2 (JWH-018) metabolites. J Anal Toxicol 2011; 35:487-495.
219. Lapoint J., James L.P., Moran C.L., Nelson L.S., et al. Severe toxicity following synthetic cannabinoid ingestion. Clin Toxicol (Phil) 2011, 49:760-764.
220. Mystakidou K., Katsouda E., Parpa E., Vlahos L., et al. Oral transmucosal fentanyl citrate: overview of pharmacological and clinical characteristics. Drug Deliv 2006, 13:269-276.
221. Kerr W.C., Greenfield T.K., Tujague J., Brown S.E. A drink is a drink? Variation in the amount of alcohol contained in beer, wine and spirits drinks in a US methodological sample. Alcohol Clin Exp Res 2005, 29:2015-2021.
222. United States Department of Agriculture and United States Department of Health and Human Services. In: Dietary guidelines for Americans. Chapter 9 - Alcoholic Beverages. Washington, DC: US Government Printing Office; 2005. p. 43-6. Available at (Accessed 7/23/2013). http://www.health.gov/DIETARYGUIDELINES/dga2005/document/html/chapter9.htm.
223. Reid M.C., Fiellin D.A., O'Connor P.G. Hazardous and harmful alcohol consumption in primary care. Arch Int Med 2008, 159:1681-1689.
224. Tolstrup J, Jensen MK, Tjonneland A, Overvad K, et al. Prospective study of alcohol drinking patterns and coronary heart disease in women and men. Br Med J 332(7552):1244-8.
225. Ruf J.C. Alcohol, wine and platelet function. Biol Res 2004, 37:209-215.
226. Rainey P. Relation between serum and whole blood ethanol concentrations. Clin Chem 1993, 39:2288-2292.
227. Logan B.K., Jones A.W. Endogenous ethanol auto brewery syndrome as a drunk-driving defense. Med Sci Law 2000, 40:206-213.
228. Jansson-Nettelbladt E., Meurling S., Petrini B., Sjolin J., et al. Endogenous ethanol fermentation in a child with short bowel syndrome. Acta Paediatr 2006, 95:502-504.
229. Jones A.W., Eklund A., Helander A. Misleading results of ethanol analysis in urine specimens from rape victim suffering from diabetes. J Clin Forensic Med 2007, 7:144-146.
230. Hoiseth G., Karinen R., Christophersen A., Morland J. Practical use of ethyl glucuronide and ethyl sulfate in postmortem cases as markers of antemortem alcohol ingestion. Int J Legal Med 2010, 124:143-148.
231. Walder AD Tyler CKG. Ethylene glycol antifreeze poisoning: Three case reports and a review of treatment. Anesthesia 1994, 49:964-967.
232. Sandberg Y., Rood P.P.M., Russcher H., Zwaans J.J.M., et al. Falsely elevated lactate in severe ethylene glycol intoxication. Netherland J Med 2010, 68:320-323.
233. Seeff L.B., Cuccherini B.A., Zimmerman H.J., Adler E., et al. Acetaminophen hepatotoxicity in alcoholics: a therapeutic misadventure. Ann Intern Med 1986, 104:399-404.
234. Davis J.E. Are one or two dangerous? Methyl salicylate exposure in toddlers. J Emerg Med 2007, 32:63-69.
235. Bell A.J., Duggin G. Acute methyl salicylate toxicity complicating herbal skin treatment for psoriasis. Emerg Med (Fremantle) 2002, 14:188-190.
236. Suner S., Partridge R., Sucov A., Valente J., et al. Non-invasive pulse CO-oximetry screening in the emergency department identifies occult carbon monoxide toxicity. J Emerg Med 2008, 34:441-450.
237. Mehrorta S., Edmonds M., Lim R.K. False elevation of carboxyhemoglobin: a case report. Pediatr Emerg Care 2011, 27:138-140.
238. Lundquist P., Rammer L., Sorbo B. The role of hydrogen cyanide and carbon monoxide in fire casualities: a prospective study. Forensic Sci Int 1989, 43:9-14.
239. Borron S.W., Baud F.J., Barriot P., Imbert M., et al. Prospective study of hydroxocobalamin for acute cyanide poisoning in smoke inhaler. Ann Emerg Med 2007, 49. 794-90.
240. Lavoie F.W., Gansert G.G., Weiss R.E. Value of initial ECG findings and plasma drug levels in cyclic antidepressant overdose. Ann Emerg Med 1990, 19:696-700.
241. Krisanda T.J. Flumazenil: an antidote for benzodiazepine toxicity. Am Fam Physician 1993, 47:891-895.
242. Gunturu K.S., Nagarjan P., McPhedran P., Goodman T.R., et al. Ayurvedic herbal medicine and lead poisoning. J Hematol Oncol 2011, 20(4):51.
243. Bernhoff R.A. Mercury toxicity and treatment: a review of literature. J Environ Public Health 2012, 2012:460508.
244. Corbett S.J., Poon C.C. Toxic levels of mercury in Chinese infants eating fish congee. Med J Aust 2008, 188:59-60.
245. Bolt H.M. Arsenic: an ancient toxicant of continuous public health impact, from Iceman to Otzi until now. Arch Toxicol 2012, 86:825-830.
246. Omakobia E., Porter G., Armstrong S., Denton K. Silicone lymphadenopathy: an unexpected case of neck lump. J Laryngol Otol 2012, 126:970-973.
247. Beutler E. Drug induced hemolytic anemia. Pharmacol Rev 1969, 21:73-103.
248. Li J., Wang S., Barone J., Malone B. Warfarin pharmacogenomics. Pharmacy Therapeutics 2009, 34:422-427.
249. Zhou S. Clinical pharmacogenomics of thiopurine S-methyltransferase. Curr Clin Pharmacol 2006, 1:119-128.
250. Fujita K., Sasaki Y. Pharmacogenomics in drug-metabolizing enzymes catalyzing anticancer drugs for personalized cancer chemotherapy. Curr Drug Metab 2007, 8:554-562.
251. Ingle J.N. Pharmacogenomics of tamoxifen and aromatase inhibitors. Cancer 2008, 112(Suppl. 3):695-699.
252. Frueh F.W., Amur S., Mummaneni P., Epstein R.S., et al. Pharmacogenomics biomarkers information in drug labels approved by the United States Food and Drug Administration: prevalence and related drug use. Pharmacotherapy 2008, 28:992-998.
253. Jannetto P.J., Bratanow N.C. Utilization of pharmacogenomics and therapeutic drug monitoring for opioid pain management. Pharmacogenomics 2009, 10:1157-1167.
254. Koren G., Cairns J., Chitayat D., Gaedigk A., et al. Pharmacogenomics of morphine poisoning in a breastfed neonate of a codeine prescribing mother. Lancet 2006, 368:704.
255. Smith J.C., Curry S.C. Prolonged toxicity after amitriptyline overdose in a patient deficient in CYP2D6 activity. J Med Toxicol 2011, 7:220-223.
256. Sheffield L.J., Ohillimore H.E. Clinical use of pharmacogenomics tests in 2009. Clin Biochem Rev 2009, 30:55-65.
257. Warne N., MacPhee I.A. Current progress in pharmacogenomics and individualized immunosuppressive drug dosing in organ transplantation. Curr Opin Mol Ther 2010, 12:270-283.
258. Kaniwa N., Saito Y., Aihara M., Matsunaga K., et al. HLA-B*1511 is a risk factor for carbamazepine induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients. Epilepsia 2010, 51:2461-2465.
259. Kostenko L., Kjer-Nielsen L., Nicholson I., Hudson F., et al. Rapid screening for the detection of HLA-B57 and HLA-B58 in prevention of drug hypersensitivity. Tissue Antigens 2011, 78:11-20.
260. Manning L.R., Russell J.R., Padovan J.C., Chait B.T., et al. Human embryonic, fetal and adult hemoglobins have different subunit interface strength. Correlation with lifespan in the red cell. Protein Sci 2007, 16:1641-1658.
261. Giordano P.C. Strategies for basic laboratory diagnostics of the hemoglobinopathies in multi-ethnic societies: interpretation of results and pitfalls. Int J Lab Hematol 2012, 35:465-479.
262. Rappaport V.J., Velazquez M., Williams K. Hemoglobinopathies in pregnancy. Obset Gynecol Clin N Am 2004, 31:287-317.
263. Sriiam S., Leecharoenkiat A., Lithanatudom P., Wannatung T., et al. Proteomic analysis of hemoglobin H Constant Spring (HB H-CS) erythroblasts. Blood Cells Mol Dis 2012, 48:77-85.
264. Yi J.S., Moertel C.L., Baker K.S. Homozygous α-thalassemia treated with intrauterine transfusion and unrelated donor hematopoietic cell transplantation. J Pediatr 2009, 154:766-768.
265. Kohne E. Hemoglobinopathies: clinical manifestations, diagnosis and treatment. Dtsch Arztebl Int 2011, 108:532-540.
266. Ngo D.A., Aygun B., Akinsheye I., Hankins J.S. Fetal hemoglobin levels and hematological characteristics of compound heterozygotes for hemoglobin S and deletional hereditary persistence of fetal hemoglobin. Br J Haematol 2012, 156:259-264.
267. Pandey S., Mishra R.M., Pandey S., Shah V., et al. Molecular characterization of hemoglobin D Punjab traits and clinical-hematological profile of patients. Sao Paulo Med J 2012, 130:248-251.
268. Dror S. Clinical and hematological features of homozygous hemoglobin O-Arab [beta 121 Glu - LYS]. Pediatr Blood Cancer 2013, 60:506-507.
269. Smaldone A. Glycemic control and hemoglobinopathy: when A1C may not be reliable. Diabetes Spectrum 2008, 21:46-49.
270. Muncie H., Campbell J.S. Alpha and beta thalassemia. Am Fam Physician 2009, 339:344-371.
271. Lubin B., Witkowska E., Kleman K. Laboratory diagnosis of hemoglobinopathies. Clin Biochem 1991, 24:363-374.
272. Benson J.A., Therell B.L. History and current status of newborn screening for hemoglobinopathies. Semin Perinatol 2010, 34:134-144.
273. Kozarski T.B., Howanitz P.J., Howanitz J.H., Lilic N., et al. Blood transfusion leading to apparent hemoglobin C, S and O-Arab hemoglobinopathies. Arch Pathol Lab Med 2006, 130:1830-1833.
274. Gupta S.K., Sharma M., Tyagi S., Pati H.P. Transfusion induced hemoglobinopathy in patients with beta-thalassemia major. Indian J Pathol Microbiol 2011, 54:609-611.
275. Agarwal A., Ghobrial I.M. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: a review of current understanding of epidemiology, biology, risk stratification, and management of myeloma precursor disease. Clin Cancer Res 2013, 19:985-994.
276. Jones C.I., Zabolotskaya M.V., King A.J., Stewart H.J., et al. Identification of circulating micro RNAs as diagnostic biomarkers for use in multiple myeloma. Br J Cancer 2012, 107:1987-1996.
277. Gregersen H., Mellemkjaer L., Ibsen J.S., Dahlerup J.F., et al. The impact of M component type and immunoglobulin concentration on the risk of malignant transformation in patients with monoclonal gammopathy of undetermined significance. Haematologica 2001, 86:1172-1179.
278. Vodopick H., Chaskes S.J., Solomon A., Stewart J.A. Transient monoclonal gammopathy associated with cytomegalovirus infection. Blood 1974, 44:189-195.
279. Gerritsen E., Vossen J., van Tol M., Jol-van der Zijde C., et al. Monoclonal gammopathies in children. J Clin Immunol 1999, 9:296-305.
280. Gras J., Padros R., Marti I., Gomez-Acha J.A. Pseudo-analbuminemia due to the presence of a slow albumin variant moving into the alpha 1 zone. Clin Chim Acta 1980, 104:125-128.
281. Mahato M., Mohapatra S., Sumitra G., Kaushik S., et al. A case of light chain deposition disease (LCDD) in a young patient. Ind J Clin Biochem 2011, 26:420-422.
282. Gay-Bellile C., Bengoufa D., Houze P., Le Carrer H., et al. Automated multi-capillary electrophoresis for analysis of human serum proteins. Clin Chem 2003, 49(11):1909-1915.
283. Roy V. Artifactual laboratory abnormalities in patients with paraproteinemia. South Med J 2009, 102:167-170.
284. Cascavilla N., Falcone A., Sanpaolo G., D'Arena G. Increased serum bilirubin level without jaundice in patients with monoclonal gammopathy. Leuk Lymphoma 2009, 50:1392-1394.
285. Hollenbeck B.L., Beckwith C.G. HIV-2 infection in Providence, Rhode Island from 2001 to 2011. HIV Med 2013, 14:115-119.
286. Luft L., Gill M.J., Church D.L. HIV-1 viral diversity and its implications for viral load testing: review of current platforms. Int J Infect Dis 2011, 15:e661-e670.
287. Gallant J.E. HIV counseling, testing and referral. Am Fam Physician 2004, 70:295-302.
288. Spivak A., Sydnor E., Blankson J.N., Gallant J.E. Seronegative HIV-1 infection: a review of the literature. AIDS 2010, 24:1407-1414.
289. Ling A.E., Robbins K.E., Brown B.S., Dunmire V., et al. Failure of routine HIV-1 tests in a case involving transmission with pre seroconversion blood components during the infection window period. JAMA 2000, 284:210-214.
290. Vardinon N., Yust I., Katz O., Laina A., et al. Anti-HIV indeterminate Western blot in dialysis patients: a long term follow up. Am J Kidney Dis 1999, 34:146-149.
291. Delaney K.P., Branson B.M., Uniyal A., Phillips S., et al. Evaluation of the performance characteristics of 6 rapid HIV antibody tests. Clin Infect Dis 2011, 52:257-263.
292. Facente S.N., Dowling T., Vittinghoff E., Sykes D.L., et al. False positive rate of rapid oral fluid HIV test increases as kits near expiration date. PLoS One 2009, 4:e8217.
293. Van Oosten H.E., Damen M., de Vries HJ Symptomatic primary HIV infection in a 49 year old man who has sex with men: beware of the window phase. Euro Surveill 2009, 14. iii.
294. Butto S., Suligoi B., Fanales-Belasio E., Raimondo M. Laboratory diagnostics for HIV infection. Ann 1st Super Sanita 2010, 46:24-33.
295. Garcia-Prats A.J., Draper H.R., Sanders J.E., Agarwal A.K., et al. False negative post 18 month confirmatory DNA PCR-positive children: a retrospective analysis. AIDS 2012, 26:1927-1934.
296. Wilkins T., Zimmerman D., Schade R.R. Hepatitis B diagnosis and treatment. Am Fam Physician 2010, 81:965-972.
297. Rysgaard C., Morris C.S., Dress D., Bebber T., et al. Positive hepatitis B surface antigen test due to recent vaccination: a persistent problem. BMC Clin Pathol 2012, 12:15.
298. Kuhns M.C., Busch M.P. New strategies for blood donor screening for hepatitis B virus: nucleic acid testing versus immunoassay methods. Mol Diag Ther 2006, 10:877-891.
299. Dow B.C., Peterkin M.A., Green R.H., Cameron O. Hepatitis B virus transmission by blood donation negative for hepatitis B surface antigen, antibody to HBsAg, antibody to hepatitis B core antigen and HBV DNA. Vox Sang 2001, 81:140.
300. Wilkins T., Malcolm J., Raina D., Sachade R. Hepatitis C: diagnosis and treatment. Am Fam Physician 2010, 81:1351-1357.
301. Kamili S., Drobeniuc J., Araujo A., Hayden T.M. Laboratory diagnostics for hepatitis C virus. Clin Infect Dis 2012, 55(Suppl. 1):S43-S48.
302. Rosenthal P. False positive results of tests for hepatitis C in autoimmune liver disease. J Pediatr 1992, 120:160-161.
303. Erickson C.P., McNiff T., Klausner J.D. Influenza vaccination and false positive HIV result. N Eng J Med 2006, 354:1422-1423.
304. Araujo P.B., Albertoni G., Arnoni C., Ribeiro J., et al. Rubella vaccination and transitory false positive results for human immunodeficiency virus Type I in blood donors. Transfusion 2009, 49:2516-2517.
305. Segerstrom S.C., Miller G.E. Psychological stress and the human immune system: a meta-analytical study of 30 years of inquiry. Psychol Bull 2004, 130:601-630.
306. Glovsky M.M., Ward P.A., Johnson K.J. Complement determinations in human disease. Ann Allergy Asthma Immunol 2004, 93:513-523.
307. Chun J.K., Lee T.J., Song J.W., Linton J.A., et al. Analysis of clinical presentation of Burton disease: a review of 20 years of accumulated data from pediatric patients at Severance Hospital. Yonsei Med 2008, 49:28-36.
308. Li Y., Yao Y., Yang M., Shi L., et al. Association between HLB-B*46 allele and Graves disease in Asian population: A meta-analysis. Int J Med Sci 2013, 10:164-170.
309. Erlich H. HLA DNA typing: past, present and future. Tissue Antigens 2012, 80:1-11.
310. Kato T., Yazawa K., Madono J., Saito J., et al. Acute graft versus host disease in kidney transplantation: case report and review of literature. Transplant Proc 2009, 41:3949-3952.
311. Lane S.K., Gravel J.W. Clinical utility of common serum rheumatologic test. Am Fam Physician 2002, 65:1073-1080.
312. Hasegawa M., Sato S., Kikuchi K., Takehara K. Antigen specificity of antihistone antibodies in systemic sclerosis. Ann Rheum Dis 1998, 57:470-475.
313. Carneiro F.O., Sampaio L.R., Brandao L.A., Braga L.L., et al. Protein losing enteropathy as initial manifestation of systemic lupus erythematosus. Lupus 2012, 21:445-448.
314. Bent S. Herbal medicine in the United States: review of efficacy, safety and regulation. J Gen Intern Med 2008, 23:854-859.
315. Cavaliere C, Rea P, Lynch M, Blumenthal M. Herbal supplement sales rise in all channels in 2009. HerbalGram 2010;86:62-65.
316. Christl S.U., Seifert A., Seeler D. Toxic hepatitis after consumption of traditional kava preparation. J Travel Med 2009, 16:55-56.
317. Denham A., McIntyre M.A., Whitehouse J. Kava-the unfolding story: report on a work-in-progress. J Alternative Complementary Med 2002, 8:237-263.
318. Vanhaelen M., Vanhaelen-Fastre R., Nut P., Abramowicz D, et al. Rapidly progressive interstitial renal fibrosis in young women: association with slimming regimen including Chinese herb. Lancet 1993, 341:387-391.
319. Teas J., Pino S., Critchley A., Braverman L.E. Variability of iodine content in common commercially available edible seaweeds. Thyroid 2004, 14:836-841.
320. Mussig K., Thamer C., Bares R., Lipp H.P., et al. Iodine induced thyrotoxicosis after ingestion of kelp containing tea. J Gen Intern Med 2006, 21:C11-C14.
321. Di Y.M., Li C.G., Xue C.C., Zhou S.F. Clinical drugs that interact with St. John's wort and implications in drug development. Curr Pharm Des 2008, 14:1723-1742.
322. Bolley R., Zulke C., Kammerl M., Fischereder M., Kramer B.K. Tacrolimus induced nephrotoxicity unmasked by induction of CYP3A4 system with St. John's wort. [Letter] Transplantation 2002, 73:1009.
323. Huang W.F., Wen K.C., Hsiao M.L. Adulteration by synthetic therapeutic substances of traditional Chinese medicine in Taiwan. J Clin Pharmacol 1997, 37:344-350.
324. Lau K.K., Lai C.K., Chan A.Y.W. Phenytoin poisoning after using Chinese proprietary medicines. Hum Exp Toxicol 2000, 19:385-386.
325. Ko R.J. Adulterants in Asian patent medicines. N Eng J Med 1998, 339:847.